PO37 | CLINICAL SIGNIFICANCE OF SYMPTOMATIC AND INCIDENTAL VENOUS THROMBOEMBOLISM IN CANCER PATIENTS TREATED WITH APIXABAN
P. Hussaini1, T.L. Larsen2, W. Ghanima1|3, A.E.A. Dahm1|2 | 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 2Department of Hematology, Akershus University Hospital; Lørenskog, Norway; 3Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background. Clinical characteristics and outcomes of cancer patients with symptomatic versus incidental venous thromboembolism (VTE) remain poorly described. This study aimed to compare clinical characteristics and outcomes in cancer patients with symptomatic versus incidental venous thromboembolism treated with apixaban.
Methods. In this post-hoc analysis of the CAP study, we explored cancer patients with VTE who received 5 mg apixaban twice daily for 6 months, followed by 2.5 mg apixaban twice daily for 30 months. Patients were classified as having symptomatic or incidental VTE at inclusion. The main outcomes were recurrent VTE and clinically relevant bleeding. Baseline characteristics and outcomes during a 36-month follow-up were compared between symptomatic and incidental VTE.
Results. Of 284 patients, 163 (57%) had incidentally detected VTE. Compared with symptomatic patients, those with incidental VTE had lower BMI, more metastatic disease (79% vs 57%), and more pulmonary and abdominal VTE. Deep vein thrombosis of the leg was higher in the symptomatic group (45.4% vs. 7.4%, p < 0.001). There was more colorectal cancer in the incidental group (31.9% vs. 19.0%, p=0.01) and more hematological (14.1% vs. 5.5%, p=0.01) and breast cancers (14.9% vs. 5.5%, p=0.01) in the symptomatic group. Recurrent VTE occurred in 9.8% of incidental and 6.6% of symptomatic cases (odds ratio (OR) 1.5, 95% confidence interval (CI) 0.6–3.7). Clinically relevant bleeding was more frequent in incidental VTE (26.4% vs. 14.9%; OR 2.1, 95% CI 1.1–3.8) (Figure 1). In a multivariable analysis incidental VTE was associated with bleeding independently of other known risk factors for bleeding, such as higher age and low hemoglobin at baseline.
Conclusions. Incidental and symptomatic VTE in cancer patients have different clinical characteristics. While VTE recurrence was similar, incidental VTE was associated with a higher risk of bleeding during apixaban therapy.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, OC11 | COMPLEXITIES IN MANAGING ANTITHROMBOTIC THERAPY IN PATIENTS WITH CANCER APPROACHING END-OF-LIFE: A MIXED METHOD INTEGRATION USING JOINT DISPLAY ANALYSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO23 | IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO DELAYED IMMUNE CHECKPOINT INHIBITORS TOXICITY: A CASE REPORT , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC12 | RISK OF VENOUS THROMBOEMBOLISM AFTER REMOVAL OF AN UPPER EXTREMITY CENTRAL CATHETER ASSOCIATED WITH A DEEP VEIN THROMBOSIS IN CANCER PATIENTS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO16 | EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND OUTCOMES OF PROVOKED AND UNPROVOKED PULMONARY EMBOLISM IN A MULTICULTURAL ISRAELI POPULATION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO43 | ELEVATED CIRCULATING TISSUE PLASMINOGEN ACTIVATOR LEVELS PREDICT GASTROINTESTINAL AND BREAST CANCER RISK: A PROSPECTIVE NESTED CASE-COHORT STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
